By Kerima Greene – CNBC
Kristen Fortney is CEO and co-founder of BioAge, a clinical stage biotech developing a pipeline of treatments to extend healthy lifespan by targeting molecular causes of aging. As a postdoctoral researcher at Stanford University, she used bioinformatics to study the genetics of supercentenarians — people who live to the age of 110 and beyond.
As a postdoctoral researcher at Stanford University, Kristen Fortney used bioinformatics to study the genetics of supercentenarians — people who live to the age of 110 and beyond. Now she is at the forefront of biotech efforts to turn longevity science knowledge into medicine. As CEO and co-founder of BioAge, a clinical stage biotech developing a pipeline of treatments to extend healthy lifespan by targeting molecular causes of aging, Fortney is working directly on a biological challenge that has attracted some of the biggest minds, and deepest pockets, in the world.
